// App-Quantinova.ai

e22042 : Circulating tumor cells (CTCs) in patients with HER2-negative recurrent or metastatic breast cancer treated with eribulin as third-line therapy: ONSITE trial (OncoSur Analysis of the Treatment in Third Line of ABC with Eribulin).

Researchers

Presenter

  • Luis Manso

Principal Investigators

  • Fernando Moreno

  • Juan Ignacio Delgado Mingorance

  • Eva Ciruelos

  • Tomas Pascual

  • Yann Izarzugaza

  • Pablo Borrega

  • Noelia Martnez

  • Clara Olier

  • Ana Isabel Ballesteros Garcia

  • Jose Ignacio Chacon

  • Luis Paz-Ares

  • Maria Jose Echarri

  • Ana Lopez-Gonzalez

Medical Centers

  • Complejo Asistencial Universitario de Leon, Leon, Spain

  • Hospital Severo Ochoa, Madrid, Spain

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • Hospital San Pedro de Alcantara, Caceres, SpainH Universitario Fundacion Alcorcon, Alcarcon, SpainMedical Oncology Department. Hospital 12 de Octubre, Madrid, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain

  • Hospital Infanta Cristina, Badajoz, Spain

  • Hospital Ramon y Cajal, Madrid, Spain

  • Hospital Universitario La Paz, Madrid, Spain

  • Hospital Virgen de la Salud, Toledo, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Eribulin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved